Skip Navigation


Journal of the National Cancer Institute Advance Access originally published online on December 25, 2007
JNCI Journal of the National Cancer Institute 2008 100(1):2-4; doi:10.1093/jnci/djm277
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow JNCI Podcast
Right arrow JNCI Podcast
Right arrow All Versions of this Article:
100/1/2    most recent
djm277v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Paik, S.
Right arrow Articles by Geyer, C. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Paik, S.
Right arrow Articles by Geyer, C. E., Jr
Related Collections
Right arrowRelated Articles in JNCI
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2007. Published by Oxford University Press.

EDITORIALS

Anthracyclines in the Treatment of HER2-Negative Breast Cancer

Soonmyung Paik, Yusuke Taniyama, Charles E. Geyer, Jr

Affiliation of authors: National Surgical Adjuvant Breast and Bowel Project (SP, YT, CEG) and Department of Human Oncology (CEG), Allegheny General Hospital, Pittsburgh, PA

Correspondence to: Soonmyung Paik, MD, Division of Pathology, National Surgical Adjuvant Breast and Bowel Project, Allegheny General Hospital, Four Allegheny Center Fifth Floor, East Commons Professional Building, Pittsburgh, PA 15212 (e-mail: soon.paik@nsabp.org).

The first 10% of the full text of this article appears below.

In this issue of the Journal, Gennari et al. (1) report results of a meta-analysis of eight published studies that tested the worth of HER2 as a predictive marker of benefit from anthracycline regimens over nonanthracycline regimens. The test for treatment by HER2 status interaction yielded statistically significant results. The authors propose that it is time to stop the use of cardiotoxic anthracycline regimens for the treatment of HER2-negative breast cancer.

Most investigations of predictive markers in the adjuvant setting have suffered from a lack of statistical power because the original trials were sized to test the efficacy of the treatment on the whole cohort rather than on the subsets defined by the markers (2). Likewise, the individual studies included in the meta-analysis lacked sufficient statistical power to convincingly demonstrate an interaction between . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Articles in JNCI

HER2 Status and Efficacy of Adjuvant Anthracyclines in Early Breast Cancer: A Pooled Analysis of Randomized Trials
Alessandra Gennari, Maria Pia Sormani, Paolo Pronzato, Matteo Puntoni, Mariantonietta Colozza, Ulrich Pfeffer, and Paolo Bruzzi
J Natl Cancer Inst 2008 100: 14-20. [Abstract] [Full Text] [PDF]

Anthracyclines Improve Survival in HER2-Positive Breast Cancer Patients
Liz Savage and Andrea Widener
J Natl Cancer Inst 2008 100: 1. [Extract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
 JCOHome page
J. M.S. Bartlett, A. Munro, D. A. Cameron, J. Thomas, R. Prescott, and C. J. Twelves
Type 1 Receptor Tyrosine Kinase Profiles Identify Patients With Enhanced Benefit From Anthracyclines in the BR9601 Adjuvant Breast Cancer Chemotherapy Trial
J. Clin. Oncol., November 1, 2008; 26(31): 5027 - 5035.
[Abstract] [Full Text] [PDF]